United States Enteral Nutrition - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states enteral nutrition market size was valued at USD 3.54 billion in 2025 and is estimated to grow from USD 3.69 billion in 2026 to reach USD 4.60 billion by 2031, at a CAGR of 4.53% during the forecast period (2026-2031). This report is Segmented by Feeding Method (Tube Feeding, Oral Feeding), Formula Type (Polymeric, Peptide-Based, Elemental, Disease-Specific), Form (Liquid, Powder), Age Group (Adults, Pediatrics), Indication (GI, Oncology, Neurology, Diabetes, CKD, Allergy, IEM), End User (Hospitals, Homecare, Long-Term Care, Specialty Clinics), and Geography (United States). Forecasts are in Value (USD).

United States Enteral Nutrition Market Trends and Insights

Aging-Related Dysphagia and Chronic Disease Burden

The aging of the U.S. population continues to create a durable demand floor for the United States enteral nutrition market through the end of the decade. This demand is not driven by age alone, because dysphagia often overlaps with dementia, stroke, Parkinson’s disease, chronic kidney disease, and head and neck cancer, which raises both treatment complexity and formula intensity. The U.S. Census Bureau projects that 73 million Americans will be age 65 or older by 2030, and that scale materially enlarges the patient base that can require oral thickened support, specialized oral nutrition, or tube feeding therapy. The United States enteral nutrition market, therefore, benefits not only from higher patient numbers but also from a richer case mix where renal, oncology, and neurologic needs push demand toward more specialized products. That pattern helps explain why disease-specific formulas are expanding faster than broad polymeric products even while the standard base remains large.

Home-Enteral Care Expansion Across Post-Acute Pathways

The center of gravity in the United States enteral nutrition market is moving from inpatient use toward the home as hospitals seek lower-cost recovery pathways and shorter lengths of stay. CMS reimbursement codes for eligible enteral products and supplies give providers a structured payment route, which makes home enteral nutrition easier to operationalize after discharge. Medicare Advantage growth is also raising plan-level formulary gatekeeping, so companies that win preferred supplier status can secure lasting distribution advantages across discharge networks. Portable pump technology and continued ENFit-compatible system adoption have narrowed the usability gap between hospital delivery and home administration, which lowers the barrier to starting patients on home regimens. As the homecare channel expands, spending also shifts toward ready-to-hang liquids and closed systems that reduce the handling burden for caregivers.

Reimbursement and Documentation Barriers for Home Enteral Nutrition

Reimbursement remains the most important structural constraint on the United States enteral nutrition market because administrative friction directly affects supplier willingness to serve home patients. CMS reported a 23.8% improper payment rate for enteral nutrition suppliers in its 2024 compliance review, and insufficient documentation accounted for 48.8% of denials, which shows how much revenue can be exposed even when clinical need is real. CMS LCD L38955 requires detailed and current proof of medical necessity, and that burden is harder for smaller homecare providers to manage without dedicated compliance teams. As those costs rise, independent distributors face tighter margins, and some exit the space, which narrows the supply base even as patient need grows. The result is a clear mismatch in the United States enteral nutrition market, because a broader eligible population is being served through a reimbursement channel that still favors scale and administrative depth.

Other drivers and restraints analyzed in the detailed report include:

• Disease-Specific Formula Adoption in Diabetes, Renal, and GI Care
• Real-Food and Blenderized Tube-Feeding Innovation
• High Affordability Pressure on Specialized Formulas

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Tube Feeding Products accounted for 64.57% of the United States enteral nutrition market share in 2025, which confirms that tube-based delivery still anchors demand across acute care and institutional settings. This position reflects persistent use in intensive care, neurology, oncology, and post-surgical recovery, where the oral route is often unavailable or insufficient for maintaining nutritional status. The United States enteral nutrition market still depends on nasogastric, nasoduodenal, and PEG-based regimens because they remain the standard of care when aspiration risk, swallowing impairment, or severe weakness limit oral intake. Hospitals and long-term care providers also value tube feeding because it provides predictable calorie and protein delivery in high-acuity patients.

Oral Feeding Products, however, are projected to grow at a 5.46% CAGR through 2031, which gives this segment the growth premium within the broader United States enteral nutrition market. Post-discharge nutrition protocols are using more oral nutritional supplements for patients leaving acute care, especially when they can transition from full tube dependence to partial or complete oral support. Managed care models are also encouraging earlier discharge, and that favors portable sip-feed formats that fit community recovery better than prolonged inpatient tube feeding. This does not weaken the clinical importance of tube products, but it does shift incremental demand toward oral supplementation as patient recovery moves outside the hospital. The result is a stable base in tube feeding and a faster expansion path for oral products, which mirrors the broader channel shift from institutional care to home and outpatient support.

Standard/Polymeric Formulas accounted for 56.81% of the United States enteral nutrition market size in 2025, while Disease-Specific Formulas are projected to expand at a 5.27% CAGR through 2031. Polymeric products still dominate because they are broadly applicable across age groups, indications, and care settings, and they remain the cost-effective workhorse of many hospital formularies. The United States enteral nutrition market retains this large polymeric base because standard formulas are easier to deploy across mixed patient populations where highly specialized composition is not required. That broad role helps preserve volume leadership even as newer categories take a larger share of incremental growth.

Disease-specific formulas are gaining ground because diabetes, renal disease, oncology, and gastrointestinal care increasingly demand nutrition profiles designed for defined metabolic or organ-related needs. Fresenius Kabi’s 2026 launch of Renalive HP shows how suppliers are targeting clinical gaps left by competitor portfolio reductions and pushing deeper into renal-specific nutrition. Peptide-based and semi-elemental formulas remain essential for patients with impaired digestion or absorption, while elemental and amino acid-based products serve the highest-complexity cases such as eosinophilic gastrointestinal disorders and inborn errors of metabolism. A 2025 review in Nutrients also supported the expanding role of amino acid-based formulas in pediatric eosinophilic esophagitis and related food protein-mediated disorders, which strengthens the reimbursement case for these products in state Medicaid programs. The United States enteral nutrition industry, therefore, continues to rely on polymeric formulas for scale, while specialized products carry the higher-value growth layer.

Complete Report Scope:

• By Feeding Method
  • Tube Feeding Products
  • Oral Feeding Products
• By Formula Type
  • Standard / Polymeric Formulas
  • Peptide-Based / Semi-Elemental Formulas
  • Elemental / Amino Acid-Based Formulas
  • Disease-Specific Formulas
• By Form
  • Liquid
  • Powder
• By Age Group
  • Adults
    • Adult 18-64
    • Geriatric 65+
  • Pediatrics
    • Infants
    • Children
    • Adolescents
• By Indication
  • Gastrointestinal Disorders and Malabsorption
    • Short Bowel Syndrome
    • Inflammatory Bowel Disease
    • Severe Malabsorption / Diarrhea
  • Oncology
  • Neurology
    • Stroke Recovery
    • Dementia / Alzheimer’s Disease
    • Cerebral Palsy and Neurodevelopmental Disorders
  • Diabetes
  • Chronic Kidney Disease
  • Food Allergy and Eosinophilic GI Disorders
  • Inborn Errors of Metabolism / Ketogenic Therapy
  • General Malnutrition / Surgical Recovery / Critical Care
• By End User
  • Hospitals
    • ICU / Critical Care
    • Med-Surg / Oncology Units
    • Neonatal / Pediatric Units
  • Homecare Settings
  • Long-term Care Centers / Skilled Nursing Facilities
  • Specialty Clinics / Outpatient Care

List of Companies Covered in this Report:

• Abbott Laboratories
• Ajinomoto Cambrooke
• B. Braun
• Cardinal Health
• Danone
• Fresenius
• Functional Formularies
• Global Health Products
• Hormel Health Labs / Lyons Health Labs
• Kate Farms
• Kent Precision Foods Group (Thick-It)
• Medline Industries
• Medtrition
• Moog Medical
• Nestlé Health Science
• Real Food Blends
• Reckitt / Mead Johnson Nutrition
• SimplyThick
• Solace Nutrition
• Vitaflo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support